|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TARS |
Gene summary for TARS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TARS | Gene ID | 6897 |
| Gene name | threonyl-tRNA synthetase 1 | |
| Gene Alias | TARS | |
| Cytomap | 5p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | P26639 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6897 | TARS | LZE4T | Human | Esophagus | ESCC | 2.95e-13 | 3.92e-01 | 0.0811 |
| 6897 | TARS | LZE7T | Human | Esophagus | ESCC | 5.03e-03 | 4.98e-01 | 0.0667 |
| 6897 | TARS | LZE8T | Human | Esophagus | ESCC | 8.89e-09 | 1.45e-01 | 0.067 |
| 6897 | TARS | LZE20T | Human | Esophagus | ESCC | 3.37e-04 | 5.54e-01 | 0.0662 |
| 6897 | TARS | LZE22D1 | Human | Esophagus | HGIN | 8.13e-03 | -8.77e-02 | 0.0595 |
| 6897 | TARS | LZE24T | Human | Esophagus | ESCC | 1.94e-10 | 6.05e-01 | 0.0596 |
| 6897 | TARS | LZE21T | Human | Esophagus | ESCC | 4.25e-02 | 1.20e-01 | 0.0655 |
| 6897 | TARS | LZE6T | Human | Esophagus | ESCC | 1.75e-16 | 1.44e+00 | 0.0845 |
| 6897 | TARS | P1T-E | Human | Esophagus | ESCC | 1.09e-07 | 8.27e-01 | 0.0875 |
| 6897 | TARS | P2T-E | Human | Esophagus | ESCC | 1.72e-21 | 6.65e-01 | 0.1177 |
| 6897 | TARS | P4T-E | Human | Esophagus | ESCC | 4.42e-30 | 9.31e-01 | 0.1323 |
| 6897 | TARS | P5T-E | Human | Esophagus | ESCC | 3.18e-21 | 7.90e-01 | 0.1327 |
| 6897 | TARS | P8T-E | Human | Esophagus | ESCC | 1.34e-16 | 5.11e-01 | 0.0889 |
| 6897 | TARS | P9T-E | Human | Esophagus | ESCC | 8.25e-14 | 3.14e-01 | 0.1131 |
| 6897 | TARS | P10T-E | Human | Esophagus | ESCC | 3.78e-45 | 1.08e+00 | 0.116 |
| 6897 | TARS | P11T-E | Human | Esophagus | ESCC | 2.57e-14 | 8.35e-01 | 0.1426 |
| 6897 | TARS | P12T-E | Human | Esophagus | ESCC | 9.42e-29 | 8.97e-01 | 0.1122 |
| 6897 | TARS | P15T-E | Human | Esophagus | ESCC | 2.43e-11 | 4.41e-01 | 0.1149 |
| 6897 | TARS | P16T-E | Human | Esophagus | ESCC | 4.30e-15 | 5.56e-01 | 0.1153 |
| 6897 | TARS | P17T-E | Human | Esophagus | ESCC | 6.42e-12 | 1.19e+00 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006418 | Colorectum | AD | tRNA aminoacylation for protein translation | 19/3918 | 41/18723 | 2.37e-04 | 3.03e-03 | 19 |
| GO:0043039 | Colorectum | AD | tRNA aminoacylation | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
| GO:0043038 | Colorectum | AD | amino acid activation | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:00064181 | Colorectum | SER | tRNA aminoacylation for protein translation | 17/2897 | 41/18723 | 5.75e-05 | 1.35e-03 | 17 |
| GO:00430391 | Colorectum | SER | tRNA aminoacylation | 17/2897 | 44/18723 | 1.64e-04 | 3.12e-03 | 17 |
| GO:00430381 | Colorectum | SER | amino acid activation | 17/2897 | 45/18723 | 2.25e-04 | 3.91e-03 | 17 |
| GO:00065201 | Colorectum | SER | cellular amino acid metabolic process | 61/2897 | 284/18723 | 4.20e-03 | 3.41e-02 | 61 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0000959 | Liver | HCC | mitochondrial RNA metabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TARS | SNV | Missense_Mutation | c.669N>C | p.Glu223Asp | p.E223D | P26639 | protein_coding | tolerated(0.47) | benign(0.007) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| TARS | SNV | Missense_Mutation | c.2044N>A | p.Asp682Asn | p.D682N | P26639 | protein_coding | deleterious(0.01) | possibly_damaging(0.838) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TARS | SNV | Missense_Mutation | novel | c.788N>A | p.Phe263Tyr | p.F263Y | P26639 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TARS | SNV | Missense_Mutation | c.1430N>C | p.Glu477Ala | p.E477A | P26639 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| TARS | SNV | Missense_Mutation | c.538N>A | p.Glu180Lys | p.E180K | P26639 | protein_coding | tolerated(0.24) | benign(0.022) | TCGA-E2-A14X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TARS | SNV | Missense_Mutation | c.1199N>A | p.Arg400Lys | p.R400K | P26639 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
| TARS | SNV | Missense_Mutation | rs747309785 | c.947N>T | p.Thr316Met | p.T316M | P26639 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E9-A1R3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | methotrexate | SD |
| TARS | insertion | Nonsense_Mutation | novel | c.1179_1180insTGAAGACTACAACGATGCTGTATGAAAAATGGATGCACAAAGCCG | p.Ile393_Arg394insTer | p.I393_R394ins* | P26639 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| TARS | insertion | Frame_Shift_Ins | novel | c.758_759insCTGGCCGTTTTGTTAC | p.Glu253AspfsTer8 | p.E253Dfs*8 | P26639 | protein_coding | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| TARS | SNV | Missense_Mutation | rs769530358 | c.2177N>G | p.Asn726Ser | p.N726S | P26639 | protein_coding | tolerated(0.06) | probably_damaging(0.976) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |